Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 11:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 1,861 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Mental Disorders, Severe Clear all
Completed Not applicable Interventional Results available

Naltrexone for Antipsychotic-Induced Weight Gain

NCT01866098
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar Disorder, Severe Major Depression With Psychotic Features
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 75 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 1, 2021 · Synced Oct 18, 2026, 11:01 AM EDT
Completed Phase 3 Interventional

Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder

NCT00411099
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
agomelatine, placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
42
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Cerritos, California + 38 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Oct 18, 2026, 11:01 AM EDT
Completed Phase 4 Interventional Results available

Abilify as an Adjunctive Treatment for Refractory Depression

NCT00220636
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Aripiprazole
Drug
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Oct 18, 2026, 11:01 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Pregnenolone for Cannabis Use Disorder and Depression

NCT07685964
View directory record Official record
Conditions
Cannabis Use Disorder, Major Depressive Disorder (MDD)
Interventions
Pregnenolone
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Dallas, Texas • Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 18, 2026, 11:01 AM EDT
Completed Phase 2 Interventional

A Study of Intermittent Doses of CERC-301 in MDD

NCT02459236
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
CERC-301, Placebo
Drug
Lead sponsor
Avalo Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
13
States / cities
Newport Beach, California • Alpharetta, Georgia • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2017 · Synced Oct 18, 2026, 11:01 AM EDT
Withdrawn No phase listed Observational

Using EEG to Predict Depression Treatment Response to rTMS in Patients With Major Depression

NCT04575285
View directory record Official record
Conditions
Major Depression, Repetitive Transcranial Magnetic Stimulation
Interventions
Electroencephalogram (EEG)
Diagnostic Test
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Oct 18, 2026, 11:01 AM EDT
Completed Not applicable Interventional

Slow-wave Sleep Deprivation in Depression

NCT01189591
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Slow-wave deprivation
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 35 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 18, 2026, 11:01 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Postpartum Video Education in High Risk Populations

NCT06310720
View directory record Official record
Conditions
Postpartum Hemorrhage, Postpartum Depression, Postpartum Sepsis, Postpartum Preeclampsia, Patient Empowerment, Patient Education, Postpartum Care
Interventions
Video Education
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 18, 2026, 11:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Does Fluoxetine Have an Effect on the CNS CRF Systems in Women Abused in Childhood?

NCT00208897
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Fluoxetine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Oct 18, 2026, 11:01 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women

NCT00406640
View directory record Official record
Conditions
Depression, Depressive Disorder, Depressive Disorder, Major
Interventions
Desvenlafaxine succinate sustained-release (DVS SR), Escitalopram
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
52
States / cities
Peoria, Arizona • Pasadena, California • San Diego, California + 46 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Oct 18, 2026, 11:01 AM EDT
Completed Phase 1 Interventional Results available

Nonconvulsive Electrotherapy: a Proof-of-concept Trial

NCT01065597
View directory record Official record
Conditions
Depressive Disorder, Bipolar Disorder, Schizoaffective Disorder
Interventions
Nonconvulsive electrotherapy
Device
Lead sponsor
University of Maryland, College Park
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 23, 2023 · Synced Oct 18, 2026, 11:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Transdiagnostic Brain-Behavior Profiling to Enhance Cognitive Behavioral Therapy Response

NCT03175068
View directory record Official record
Conditions
Major Depressive Disorder, Social Anxiety Disorder
Interventions
CBT, ST
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
203 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 18, 2026, 11:01 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Technology Enhanced Family Treatment

NCT03913013
View directory record Official record
Conditions
Mood Disorders, Bipolar Disorder, Major Depression
Interventions
Family-Focused Treatment with MCC App
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
13 Years to 19 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Oct 18, 2026, 11:01 AM EDT
Withdrawn Not applicable Interventional

Waitlist-Control Trial of Smartphone CBT for Major Depressive Disorder (MDD), Withdrawn

NCT03769350
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Smartphone-delivered CBT for MDD
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 18, 2026, 11:01 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Abuse Potential of Oxymorphone Compared to Other Mu Opioid Agonists.

NCT03389750
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Intravenous Challenge Drug
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Lexington, Kentucky • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 18, 2026, 11:01 AM EDT
Completed Phase 3 Interventional Results available

Safety of REL-1017 for Major Depressive Disorder

NCT04855760
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
REL-1017
Drug
Lead sponsor
Relmada Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
627 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
9
States / cities
Miami, Florida • Orlando, Florida • Palm Bay, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Oct 18, 2026, 11:01 AM EDT
Completed Phase 4 Interventional Results available

Acamprosate Added to Escitalopram and Behavioral Treatment for Comorbid Depression and Alcoholism

NCT00452543
View directory record Official record
Conditions
Major Depressive Disorder, Alcohol Abuse, Alcohol Dependence
Interventions
acamprosate, escitalopram, Medical management, Placebo
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2012 · Synced Oct 18, 2026, 11:01 AM EDT
Completed Phase 3 Interventional Results available

Escitalopram (Lexapro) for Depression MS or ALS

NCT00965497
View directory record Official record
Conditions
Major Depression, Multiple Sclerosis, Amyotrophic Lateral Sclerosis
Interventions
escitalopram
Drug
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Oct 18, 2026, 11:01 AM EDT
Recruiting Not applicable Interventional

Closed-Loop Deep Brain Stimulation for Treatment-Resistant Bipolar Depression

NCT07127913
View directory record Official record
Conditions
Bipolar II Disorder, Bipolar II Disorder, Most Recent Episode Major Depressive
Interventions
Device: Stimulation-ON, Device: Stimulation-OFF, Device: Stimulation -ON Active Control
Device
Lead sponsor
Andrew Krystal
Other
Eligibility
22 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 18, 2026, 11:01 AM EDT
Completed Phase 2 Interventional Results available

Buprenorphine for Late-Life Treatment Resistant Depression

NCT01071538
View directory record Official record
Conditions
Depression
Interventions
Buprenorphine
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2018 · Synced Oct 18, 2026, 11:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function

NCT00824590
View directory record Official record
Conditions
Alzheimer's Disease, Huntington's Disease
Interventions
Dimebon
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
2
States / cities
Miami, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 30, 2009 · Synced Oct 18, 2026, 11:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Brain on Whole Body Hyperthermia: A Neuroimaging Study

NCT02062840
View directory record Official record
Conditions
Major Depression
Interventions
High intensity whole-body infrared heating, Low intensity whole-body infrared heating, Functional Magnetic Resonance Imaging (fMRI) and electrocardiogram (EKG), Questionnaires
Device · Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 30 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 10, 2015 · Synced Oct 18, 2026, 11:01 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive Disorder

NCT01838876
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cariprazine, Antidepressant Therapy (ADT)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
88
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Little Rock, Arkansas + 74 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 18, 2026, 11:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2216684 in Healthy Participants Receiving Albuterol or Propanolol

NCT01263197
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY2216684, albuterol, propranolol, placebo for LY2216684, placebo for albuterol, placebo for propranolol
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Oct 18, 2026, 11:01 AM EDT